TY - JOUR
T1 - Twelve weeks of resistance training does not influence peripheral levels of neurotrophic growth factors or homocysteine in healthy adults
T2 - a randomized-controlled trial
AU - Marston, Kieran J.
AU - Brown, Belinda M.
AU - Rainey-Smith, Stephanie R.
AU - Bird, Sabine
AU - Wijaya, Linda
AU - Teo, Shaun Y.M.
AU - Laws, Simon M.
AU - Martins, Ralph N.
AU - Peiffer, Jeremiah J.
N1 - Funding Information:
BMB is supported by the NHMRC National Institute of Dementia Research (GNT1097105). SRRS is supported by a BrightFocus Foundation Fellowship. RNM is the Founder and owns stock in Alzhyme.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/10
Y1 - 2019/10
N2 - Introduction: There is growing evidence for a preventative effect of resistance training on cognitive decline through physiological mechanisms; yet, the effect of resistance training on resting growth factors and homocysteine levels is incompletely understood. This study aimed to investigate the effect of intense resistance training, for 12 weeks, on changes in peripheral growth factors and homocysteine in late middle-aged adults. Methods: 45 healthy adults were enrolled into the single-site parallel groups’ randomized-controlled trial conducted at the Department of Exercise Science, Strength and Conditioning Laboratory, Murdoch University. Participants were allocated to the following conditions: (1) high-load resistance training (n = 14), or (2) moderate-load resistance training (n = 15) twice per week for 12 weeks; or (3) non-exercising control group (n = 16). Data were collected from September 2016 to December 2017. Fasted blood samples were collected at baseline and within 7 days of trial completion for the analysis of resting serum brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1, vascular endothelial growth factor, and plasma homocysteine levels. Results: No differences in baseline to post-intervention change in serum growth factors or plasma homocysteine levels were observed between groups. A medium effect was calculated for BDNF change within the high-load condition alone (+ 12.9%, g = 0.54). Conclusions: High-load or moderate-load resistance training twice per week for 12 weeks has no effect on peripheral growth factors or homocysteine in healthy late middle-aged adults. Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12616000690459.
AB - Introduction: There is growing evidence for a preventative effect of resistance training on cognitive decline through physiological mechanisms; yet, the effect of resistance training on resting growth factors and homocysteine levels is incompletely understood. This study aimed to investigate the effect of intense resistance training, for 12 weeks, on changes in peripheral growth factors and homocysteine in late middle-aged adults. Methods: 45 healthy adults were enrolled into the single-site parallel groups’ randomized-controlled trial conducted at the Department of Exercise Science, Strength and Conditioning Laboratory, Murdoch University. Participants were allocated to the following conditions: (1) high-load resistance training (n = 14), or (2) moderate-load resistance training (n = 15) twice per week for 12 weeks; or (3) non-exercising control group (n = 16). Data were collected from September 2016 to December 2017. Fasted blood samples were collected at baseline and within 7 days of trial completion for the analysis of resting serum brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1, vascular endothelial growth factor, and plasma homocysteine levels. Results: No differences in baseline to post-intervention change in serum growth factors or plasma homocysteine levels were observed between groups. A medium effect was calculated for BDNF change within the high-load condition alone (+ 12.9%, g = 0.54). Conclusions: High-load or moderate-load resistance training twice per week for 12 weeks has no effect on peripheral growth factors or homocysteine in healthy late middle-aged adults. Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12616000690459.
KW - Cognitive decline
KW - Growth factors
KW - Homocysteine
KW - Preventative medicine
KW - Strength training
UR - http://www.scopus.com/inward/record.url?scp=85070093739&partnerID=8YFLogxK
U2 - 10.1007/s00421-019-04202-w
DO - 10.1007/s00421-019-04202-w
M3 - Article
C2 - 31372803
AN - SCOPUS:85070093739
SN - 1439-6319
VL - 119
SP - 2167
EP - 2176
JO - European Journal of Applied Physiology
JF - European Journal of Applied Physiology
IS - 10
ER -